title: [Therapeutic update in hepatitis C].
abstract: Hepatitis C virus infection is a major health burden affecting 130-170 million people worldwide. Approximately 10-30% of those with chronic hepatitis C will progress to cirrhosis over 20-30 years. The development of new direct-acting antivirals has changed the management of the disease, allowing efficacious Interferon-free therapies superior to prior treatment regimens with minimal side effects, even in some subgroups previously thought to be difficult to cure such as cirrhotic patients.
authors.affiliation: María José Devesa, Servicio de Aparato Digestivo. Hospital Clínico San Carlos, Madrid, Spain. mjdevesa@yahoo.es.
authors.forename: María José
authors.initials: MJ
authors.lastname: Devesa
authors.forename: Francisca
authors.initials: F
authors.lastname: Cuenca
authors.forename: Sonia
authors.initials: S
authors.lastname: Izquierdo
authors.forename: Pilar
authors.initials: P
authors.lastname: Sánchez-Pobre
authors.forename: José María
authors.initials: JM
authors.lastname: Ladero
authors.forename: Gustavo
authors.initials: G
authors.lastname: López-Alonso
authors.forename: Manuel
authors.initials: M
authors.lastname: Díaz-Rubio
authors.forename: Enrique
authors.initials: E
authors.lastname: Rey
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016174:Hepacivirus; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000209:etiology
chemical_list: D000998:Antiviral Agents